Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05840224 · ClinicalTrials.gov registry record · Phase 1
Study of GS-4528 in Adults With Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 1
- Development phase
- 182
- Enrollment target
- 16
- Study locations
NCT05840224 is a Phase 1 study of Solid Tumor that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 182 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (18% lower). The trial reports 16 study locations across 2 states.
The verdict
NCT05840224, a Phase 1 study of Solid Tumor, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 182 participants
- Enrollment target
- 16
- Study locations
Study Summary
The goals of this clinical study are to identify if GS-4528 alone or in combination with anti-programmed cell death protein 1 (PD-1) (Anti-PD-1) Monoclonal Antibody is safe and tolerable in people with solid tumors and to identify the recommended dose of GS-4528 for further development that is safe to give to people alone or in combination with Anti-PD-1 Monoclonal Antibody. The primary objectives of this study are: * To assess the safety and tolerability of GS-4528 as monotherapy and in combination with Anti-PD-1 Monoclonal Antibody in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and/or the recommended Phase 2 dose (RP2D) of GS-4528 as monotherapy and in combination with Anti-PD-1 Monoclonal Antibody in participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Zimberelimab
- BIOLOGICAL GS-4528
Study Locations (16)
Other
- The Ottawa Hospital - Ottawa
- University Health Network, Princess Margaret Cancer Centre - Toronto
- Asan Medical Center - Seoul
- Severance Hospital, Yonsei University Health Systems - Seoul
- Samsung Medical Center - Seoul
- NEXT Oncology-Hospital Quironsalud Barcelona - Unidad de Ensayos Fase 1 - Barcelona
- Hospital Universitari Vall D'Hebron- Oncology Service - Barcelona
- START MADRID_Hospital Universitario Fundacion Jimenez Diaz - Unidad de Ensayos Fases I - Madrid
- START MADRID_HM Sanchinarro-CIOCC-Unidad de Ensayos Fases I - Madrid
- Clinica Universidad de Navarra- Unidad Central de Ensayos Clinicos - Pamplona
- Taichung Veterans General Hospital - Taichung
- National Taiwan University Hospital - Taipei
- Chang Gung Memorial Hospital Linkuo Branch of the Chang Gung Medical Foundation - Taoyuan District
- St Bartholomew's Hospital - London
- The Royal Marsden NHS Foundation Trust - Sutton
Washington
- The University of Washington/FHCC - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2023-05-11 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05840224
The ClinicalTrials.gov registry entry for NCT05840224 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (18% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Zimberelimab is the first listed.
NCT05840224 reports 16 study locations spanning 2 distinct geographic areas - top geographies include Other, Washington.
Frequently Asked Questions
What is clinical trial NCT05840224 about?
NCT05840224 is a clinical study titled "Study of GS-4528 in Adults With Solid Tumors". The goals of this clinical study are to identify if GS-4528 alone or in combination with anti-programmed cell death protein 1 (PD-1) (Anti-PD-1) Monoclonal Antibody is safe and tolerable in people with solid tumors and to identify the recommended dose of GS-4528 for further development that is safe ...
What is the current status of trial NCT05840224?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 182 participants. The study started on 2023-05-11. Estimated completion is 2026-07.
What conditions does trial NCT05840224 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05840224?
The interventions under investigation include: Zimberelimab (DRUG), GS-4528 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05840224?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05840224 being conducted?
This trial has 16 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.